Continuous daily sunitinib for recurrent glioblastoma
Continuous daily sunitinib for recurrent glioblastoma
About this item
Full title
Author / Creator
Publisher
Boston: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Springer US
Subjects
More information
Scope and Contents
Contents
Bevacizumab ((BEV) has become a mainstay of treating recurrent glioblastoma, but eventual tumor resistance is expected. Targeting multiple growth-associated signaling pathways may result in more effective treatment than targeting VEGF alone. Patients with recurrent glioblastoma were stratified by prior BEV exposure and treated with sunitinib 37.5 m...
Alternative Titles
Full title
Continuous daily sunitinib for recurrent glioblastoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1291613487
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1291613487
Other Identifiers
ISSN
0167-594X
E-ISSN
1573-7373
DOI
10.1007/s11060-012-0988-z
